WO1989009058A1 - Pharmaceutical preparation containing a fluoride salt - Google Patents
Pharmaceutical preparation containing a fluoride salt Download PDFInfo
- Publication number
- WO1989009058A1 WO1989009058A1 PCT/EP1989/000326 EP8900326W WO8909058A1 WO 1989009058 A1 WO1989009058 A1 WO 1989009058A1 EP 8900326 W EP8900326 W EP 8900326W WO 8909058 A1 WO8909058 A1 WO 8909058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical preparation
- acid
- methyl
- fluoride salt
- oestren
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a pharmaceutical preparation containing a fluoride salt.
- Such preparations are known, in particular for treating osteoporosis.
- Fluoride salts such as, for example, NaF and Na 2 PO 3 F stimulate the trabecular bone substance and are therefore suitable for treating osteoporosis.
- a disadvantage of such preparations is that they cause cortical bone loss and a change in the structure of the cortical bone. As a consequence thereof, the bone becomes more brittle, which has in turn the consequence that more frequent and ready bone fractures, in particular hip fractures, occur.
- bone-protecting steroids are used to prevent and/or treat osteoporosis and more generally, diseases which are the result of excessively low bone substance.
- the invention therefore relates to a pharmaceutical preparation containing a fluoride salt and a steroid with the general formula:
- R 1 H 2 , H(OR 5 ) or 0;
- R 2 ( ⁇ R 6 ) ( ⁇ OR 7 ) ;
- R 3 H or (1-4 C)alkyl in position 6 or 7;
- R 4 (1-4 C)alkyl
- R 5 H or (1-18 C)acyl
- R 6 H or (1-4 C) hydrocarbon radical
- R 7 H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5, 10-position.
- (1-4 C)Alkyl is understood to mean methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl.
- R 3 is preferably methyl and is, in addition, preferably situated in the ⁇ -position.
- R 4 is preferably methyl.
- (1-18 C) acyl is derived from an organic carboxylic acid containing 1-18 carbon atoms.
- an organic carboxylic acid containing 1-18 carbon atoms As examples thereof mention may be made of: formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, trimethylacetic acid, valeric acid, caproic acid, capric acid, pelargonic acid, undecylenic acid, lauric acid, palmitic acid, oleic acid, phenylacetic acid, phenylpropionic acid, cyclopentylpropionic acid, cyclohexylcarboxylic acid, cyclooctylacetic acid, benzoic acid, fumaric acid, maleic acid, succinic acid, citric acid.
- Hydrocarbon radical is understood to mean one of the groups designated above as (1-4 C)alkyl or an unsaturated variant thereof containing 2-4 carbon atoms, such as vinyl, ethynyl, allyl, propargyl, isopropenyl, butynyl or butadienyl.
- R 6 is preferably ethynyl, R 7 then preferably being H.
- Salts which are readily soluble in water such as NaF, KF and Na 2 PO 3 F are preferably used as fluoride salts. The greatest preference is for Na 2 PO 3 F.
- steroids having the formula I which may be used according to the invention are: 17 ⁇ -ethyl-17 ⁇ -hydroxy- ⁇ 4 -oestrene, 17 ⁇ -hydroxy- ⁇ 4 -oestren-3-one,
- the pharmaceutical preparations according to the invention can be prepared by known galenical techniques by converting the respective steroid compound and the fluoride salt into a form which is suitable for enteral (for example, oral or rectal, and preferably oral) use.
- enteral for example, oral or rectal, and preferably oral
- the steroid compound and the fluoride salt are mixed with or dissolved in a pharmaceutically acceptable carrier.
- Such preparations are tablets, pills, dragees, pastilles, suppositories, powders, (micro) capsules, emulsions, suspensions and solutions.
- the quantity of steroid in the preparation to be administered is 0.05-10.0 mg and usually 0.1-5.0 mg.
- the quantity of fluoride salt in the preparations to be administered is 1-250 mg and usually 10-100 mg.
- the daily dosage is usually 1-3 dosage units.
- the pharmaceutically acceptable carriers may be composed of one or more of the following ingredients: starch (for example, potato starch, maize starch), sugars (for example, lactose), lubricants (magnesium stearate, stearic acid), binders (for example, amylopectin, polyvinylpyrrolidone), water, alcohol, glycerol and derivatives thereof, vegetable, animal and mineral oils and fats, fatty alcohols, silicones, lanolins, polyalkylene glycols, cellulose derivatives, silica, dispersants, emulsifiers, surface active substances, antioxidants, preservatives, etc.
- starch for example, potato starch, maize starch
- sugars for example, lactose
- lubricants magnesium stearate, stearic acid
- binders for example, amylopectin, polyvinylpyrrolidone
- water for example, alcohol, glycerol and derivatives thereof, vegetable, animal and
- the preparations according to the invention may suitably be used to prevent and/or treat diseases which occur as a consequence of an excessively low bone substance and in particular, of osteoporosis.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to a pharmaceutical preparation containing a fluoride salt and a steroid with the general formula (I), wherein R1 = H2, H(OR5) or O; R2 = (alphaR6) (betaOR7; R3 = H or (1-4 C)alkyl in position 6 or 7; R4 = (1-4 C)alkyl; R5 = H or (1-18 C)acyl; R6 = H or (1-4 C)hydrocarbon radical; R7 = H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5,10-position.
Description
Pharmaceutical preparation containing a fluoride salt.
The invention relates to a pharmaceutical preparation containing a fluoride salt.
Such preparations are known, in particular for treating osteoporosis. Fluoride salts such as, for example, NaF and Na2PO3F stimulate the trabecular bone substance and are therefore suitable for treating osteoporosis. A disadvantage of such preparations is that they cause cortical bone loss and a change in the structure of the cortical bone. As a consequence thereof, the bone becomes more brittle, which has in turn the consequence that more frequent and ready bone fractures, in particular hip fractures, occur.
It is further known that bone-protecting steroids are used to prevent and/or treat osteoporosis and more generally, diseases which are the result of excessively low bone substance.
Surprisingly, it has now been found that by using certain steroids in combination with said fluoride salts for preventing and/or treating such diseases and, in particular, osteoporosis, the disadvantages associated with the use of said fluoride salts can be reduced and/or be avoided.
The invention therefore relates to a pharmaceutical preparation containing a fluoride salt and a steroid with the general formula:
R1 = H2, H(OR5) or 0;
R2 = (αR6) (βOR7) ;
R3 = H or (1-4 C)alkyl in position 6 or 7;
R4 = (1-4 C)alkyl;
R5 = H or (1-18 C)acyl;
R6 = H or (1-4 C) hydrocarbon radical;
R7 = H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5, 10-position.
(1-4 C)Alkyl is understood to mean methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl. R3 is preferably methyl and is, in addition, preferably situated in the α-position. R4 is preferably methyl.
As is already indicated by the affix (1-18 C), (1-18 C) acyl is derived from an organic carboxylic acid containing 1-18 carbon atoms. As examples thereof mention may be made of: formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, trimethylacetic acid, valeric acid, caproic acid, capric acid, pelargonic acid, undecylenic acid, lauric acid, palmitic acid, oleic acid, phenylacetic acid, phenylpropionic acid, cyclopentylpropionic acid, cyclohexylcarboxylic acid, cyclooctylacetic acid, benzoic acid, fumaric acid, maleic acid, succinic acid, citric acid.
(1-4 C) Hydrocarbon radical is understood to mean one of the groups designated above as (1-4 C)alkyl or an unsaturated variant thereof containing 2-4 carbon atoms, such as vinyl, ethynyl, allyl, propargyl, isopropenyl, butynyl or butadienyl.
R6 is preferably ethynyl, R7 then preferably being H.
Salts which are readily soluble in water such as NaF, KF and Na2PO3F are preferably used as fluoride salts. The greatest preference is for Na2PO3F.
Examples of steroids having the formula I which may be used according to the invention are: 17α-ethyl-17β-hydroxy-Δ4-oestrene, 17β-hydroxy-Δ4-oestren-3-one,
7α-methyl-17α-ethynyl-17β-hydroxy-Δ5(10)-oestren-3-one, 7α-methyl-17α-ethynyl-Δ5(10)-oestren-17β-ol, 7α-methyl-17α-ethynyl-17β-hydroxy-Δ4-oestren-3-one, 7α-methyl-17α-ethyl-17β-hydroxy-Δ5(10)-oestren-3-one, 7α-methyl-17α-ethynyl-Δ5(10)-oestrene-3α,17β-diol, 7α-methyl-17α-ethynyl-Δ5(10)-oestrene-3β,17β-diol, 7α-methyl-17α-allyl-17β-hydroxy-Δ5(10)-oestren-3-one, 7α,17α-dimethyl-170-hydroxy-Δ4-oestren-3-one, 7o;-methyl-17α-ethynyl-Δ4-oestrene-3β,17β-diol, 6α-methyl-17β-hydroxy-Δ4-oestren-3-one, 6α-methyl-17β-hydroxy-Δ4-oestren-3-one, 6α-methyl-17α-ethynyl-17β-hydroxy-Δ4-oestren-3-one, 6α-methyl-17α-ethyl-17β-hydroxy-Δ4-oestren-3-one, 6α-methyl-17α-ethynyl-Δ4-oestren-17β-ol, 6α-methyl-17α-ethynyl-17β-hydroxy-Δ5(10)-oestren-3-one, 6α-methyl-17α-allyl-17β-hydroxy-Δ5(10)-oestren-3-one, and esters thereof. The greatest preference is for 7α-methyl-17α-ethynyl-17β-hydroxy-Δ5(10)-oestren-3-one.
The pharmaceutical preparations according to the invention can be prepared by known galenical techniques by converting the respective steroid compound and the fluoride salt into a form which is suitable for enteral (for example, oral or rectal, and preferably oral) use. For this purpose, the steroid compound and the fluoride salt are mixed with or dissolved in a pharmaceutically acceptable carrier.
Examples of such preparations are tablets, pills, dragees, pastilles, suppositories, powders, (micro) capsules, emulsions, suspensions and solutions.
The quantity of steroid in the preparation to be administered is 0.05-10.0 mg and usually 0.1-5.0 mg. The quantity of fluoride salt in the preparations to be administered is 1-250 mg and usually 10-100 mg. The daily dosage is usually 1-3 dosage units.
The pharmaceutically acceptable carriers may be composed of one or more of the following ingredients: starch (for example, potato starch, maize starch), sugars (for example, lactose), lubricants (magnesium stearate, stearic acid), binders (for example, amylopectin, polyvinylpyrrolidone), water, alcohol, glycerol and derivatives thereof, vegetable, animal and mineral oils and fats, fatty alcohols, silicones, lanolins, polyalkylene glycols, cellulose derivatives, silica, dispersants, emulsifiers, surface active substances, antioxidants, preservatives, etc.
The preparations according to the invention may suitably be used to prevent and/or treat diseases which occur as a consequence of an excessively low bone substance and in particular, of osteoporosis.
The invention is explained on the basis of the following examples.
Example 1 (tablet)
7α-Methyl-17α-ethynyl-17/3-hydroxy- Δ5(10)-oestren-3-one, 2.5 mg
Na2PO3F 50.0 mg
Potato starch 25.0 mg
Magnesium stearate 1.25 mg
Ascorbyl palmitate 0.5 mg
Amylopectin 5.0 mg
Lactose to 250.0 mg
Example 2 (tablet)
7α-Methyl-17α-ethyl-17β-hydroxy- Δ5(10)-oestren-3-one, 2.0 mg
Na2PO3F 30.0 mg
Maize starch 25.0 mg
Stearic acid 2.5 mg
Silica ("Aerosil") 2.5 mg
Polyvinylpyrrolidone 7.5 mg dl-α-Tocopherol 0.25 mg
Lactose to 250.0 mg
Example 3 (tablet)
7α-Methyl-17α-ethynyl-17β--ydroxy- Δ4-oestren-3-one, 5.0 mg
Na2PO3F 50.0 mg
Potato starch 62.5 mg
Magnesium stearate 10.0 mg dl-α-Tocopherol 0.5 mg
Lactose to 250.0 mg
Claims
1. Pharmaceutical preparation containing a fluoride salt and a steroid with the general formula:
R1 = H2, H(OR5) or 0;
R2 = (αR6) (βOR7);
R3 = H or (1-4 C)alkyl in position 6 or 7;
R4 = (1-4 C)alkyl;
R5 = H or (1-18 C)acyl;
R6 = H or (1-4 C)hydrocarbon radical;
R7 = H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5,10-position.
2. Pharmaceutical preparation according to Claim 1, characterized in that the fluoride salt is water- soluble.
3. Pharmaceutical preparation according to Claim 1-2, characterized in that the fluoride salt is a sodium salt.
4. Pharmaceutical preparation according to Claim 1-3, characterized in that the fluoride salt is Na2PO3F.
5. Pharmaceutical preparation according to Claim 1-4, characterized in that the steroid is 7α-methyl-17α- ethynyl-17β-hydroxy-Δ5(10)-oestren-3-one.
6. Pharmaceutical preparation according to Claim 1-5, characterized in that the quantity of steroid is 0.05-10.0 mg.
7. Pharmaceutical preparation according to Claim 1-6, characterized in that the quantity of salt is 1-250 mg,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK224690A DK224690D0 (en) | 1988-03-25 | 1990-09-18 | PHARMACEUTICAL PREPARATION CONTAINING A FLUORIDE SALT |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8800749 | 1988-03-25 | ||
| NL8800749 | 1988-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1989009058A1 true WO1989009058A1 (en) | 1989-10-05 |
Family
ID=19852000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1989/000326 Ceased WO1989009058A1 (en) | 1988-03-25 | 1989-03-24 | Pharmaceutical preparation containing a fluoride salt |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0406279A1 (en) |
| JP (1) | JPH03503414A (en) |
| AU (1) | AU3435989A (en) |
| DK (1) | DK224690D0 (en) |
| WO (1) | WO1989009058A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0455503A1 (en) * | 1990-05-04 | 1991-11-06 | Colgate-Palmolive Company | Composition for treating osteoporosis and hormonal imbalance |
| DE4236090C1 (en) * | 1992-10-26 | 1994-01-05 | Asta Medica Arzneimittel | Pharmaceutical preparation for fluoride ion supply |
| WO2000023460A1 (en) * | 1998-10-16 | 2000-04-27 | Akzo Nobel N.V. | HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3287219A (en) * | 1963-08-05 | 1966-11-22 | Charles J Nemanick | Method of healing bone fractures |
-
1989
- 1989-03-24 JP JP1503954A patent/JPH03503414A/en active Pending
- 1989-03-24 WO PCT/EP1989/000326 patent/WO1989009058A1/en not_active Ceased
- 1989-03-24 EP EP89903712A patent/EP0406279A1/en not_active Withdrawn
- 1989-03-24 AU AU34359/89A patent/AU3435989A/en not_active Abandoned
-
1990
- 1990-09-18 DK DK224690A patent/DK224690D0/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3287219A (en) * | 1963-08-05 | 1966-11-22 | Charles J Nemanick | Method of healing bone fractures |
Non-Patent Citations (1)
| Title |
|---|
| Rote Liste, 1980, Editio Cantor (Aulendorf, Wurtt., DE), no. 61051 B, "Calstabil" * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0455503A1 (en) * | 1990-05-04 | 1991-11-06 | Colgate-Palmolive Company | Composition for treating osteoporosis and hormonal imbalance |
| GR910100192A (en) * | 1990-05-04 | 1992-07-30 | Colgate Palmolive Co | Method for preparing a composition for the osteoporosis and hormone imbalance treatment |
| DE4236090C1 (en) * | 1992-10-26 | 1994-01-05 | Asta Medica Arzneimittel | Pharmaceutical preparation for fluoride ion supply |
| WO2000023460A1 (en) * | 1998-10-16 | 2000-04-27 | Akzo Nobel N.V. | HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE |
| US6969708B1 (en) | 1998-10-16 | 2005-11-29 | Akzo Nobel N.V. | Process for the preparation of a high purity composition comprising (7α, 17α)- 17-hydroxy- 7-methyl- 19-nor-17-pregn-5(10)-en-20-yn-3-one |
| CN100378116C (en) * | 1998-10-16 | 2008-04-02 | 欧加农股份有限公司 | High purity compositions comprising (7 alpha, 17 alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en-20-yn-3-one |
Also Published As
| Publication number | Publication date |
|---|---|
| DK224690A (en) | 1990-09-18 |
| JPH03503414A (en) | 1991-08-01 |
| DK224690D0 (en) | 1990-09-18 |
| AU3435989A (en) | 1989-10-16 |
| EP0406279A1 (en) | 1991-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5116828A (en) | Pharmaceutical composition for treatment of osteoporosis | |
| CA2001618C (en) | Gestodene-containing agent for transdermal administration | |
| JP2965160B2 (en) | Compositions that achieve contraception | |
| KR101019361B1 (en) | Pharmaceutical combination of ethynylestradiol and drospirenone for use as contraceptive | |
| EP1272505B1 (en) | 8beta-substituted-11beta-pentyl- and 11beta-hexyl-estra-1,3,5(10)-triene derivatives | |
| EP0309263B1 (en) | Hormone composition and use | |
| JPS6245845B2 (en) | ||
| JPH0680072B2 (en) | Estriol ester, process for producing the same and depot contraceptive containing the compound | |
| US3859437A (en) | Reducing cholesterol levels | |
| AU756739B2 (en) | Testosterone derivative | |
| WO1992000010A1 (en) | Method of treating human prostatic adenocarcinoma | |
| RU2482853C2 (en) | Pharmaceutical composition, method for preparing it and multiphase pharmaceutical preparation for ovulation inhibition in mammal | |
| US5482935A (en) | Anti-atherosclerotic use of 17 alpha-dihydroequilin | |
| JP2004524354A (en) | Estrogen replacement therapy | |
| WO1989009058A1 (en) | Pharmaceutical preparation containing a fluoride salt | |
| AU671706B2 (en) | Use of a Pregnane Derivative | |
| JPS62201819A (en) | Treatment for immunodeficiency | |
| JP2779931B2 (en) | Psoriasis treatment | |
| US4794119A (en) | Aqueous crystalline suspension of steroid glycoesters | |
| EP1423407B1 (en) | 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds | |
| NZ236755A (en) | Composition for alleviating menopausal symptoms comprising melatonin and an estrogen and/or an androgen. | |
| JPH0759505B2 (en) | Osteogenesis promoter containing cyclopentenones as active ingredients | |
| MXPA00012805A (en) | Testosterone derivative | |
| GB1572488A (en) | 1-hydroxy- 4-3-keto-estrenes and their use | |
| JPH02240097A (en) | Treatment using cyanprogesterone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1989903712 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1989903712 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1989903712 Country of ref document: EP |